Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI 48109, USA.
Immunotherapy. 2023 Jul;15(10):713-727. doi: 10.2217/imt-2022-0299. Epub 2023 Apr 27.
The JAK signaling pathway plays a major role in the immunopathology of autoimmune diseases, including inflammatory bowel disease. JAK enzymes provide novel targets for rapidly effective inflammatory bowel disease therapy, particularly in ulcerative colitis. Upadacitinib is a targeted JAK1 inhibitor. In multiple phase III clinical trials, upadacitinib has demonstrated significant improvement in clinical and endoscopic outcomes and quality of life for patients with moderate-to-severe ulcerative colitis. In this drug evaluation we describe the role of the JAK signaling pathway in ulcerative colitis, the mechanism of action of upadacitinib and the current clinical evidence for its use in ulcerative colitis; we also review its safety and tolerability, including for special populations.
JAK 信号通路在自身免疫性疾病的免疫病理学中起着重要作用，包括炎症性肠病。JAK 酶为快速有效的炎症性肠病治疗提供了新的靶点，特别是在溃疡性结肠炎中。Upadacitinib 是一种靶向 JAK1 的抑制剂。在多项 III 期临床试验中，Upadacitinib 已证明对中重度溃疡性结肠炎患者的临床和内镜结局以及生活质量有显著改善。在本药物评价中，我们描述了 JAK 信号通路在溃疡性结肠炎中的作用、Upadacitinib 的作用机制以及其在溃疡性结肠炎中的临床应用证据；我们还回顾了其安全性和耐受性，包括特殊人群。
